These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer. Tang S; Yuan X; Song J; Chen Y; Tan X; Li Q Oncol Lett; 2019 Jan; 17(1):159-164. PubMed ID: 30655751 [TBL] [Abstract][Full Text] [Related]
43. The role of STATs in transcriptional control and their impact on cellular function. Bromberg J; Darnell JE Oncogene; 2000 May; 19(21):2468-73. PubMed ID: 10851045 [TBL] [Abstract][Full Text] [Related]
44. Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma. Ilamathi M; Santhosh S; Sivaramakrishnan V Curr Top Med Chem; 2016; 16(22):2453-63. PubMed ID: 26873192 [TBL] [Abstract][Full Text] [Related]
45. The JAK/STAT signaling cascade in gastric carcinoma (Review). Khanna P; Chua PJ; Bay BH; Baeg GH Int J Oncol; 2015 Nov; 47(5):1617-26. PubMed ID: 26398764 [TBL] [Abstract][Full Text] [Related]
46. Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism. Nan Y; Wu C; Zhang YJ Front Immunol; 2017; 8():1758. PubMed ID: 29312301 [TBL] [Abstract][Full Text] [Related]
47. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660 [TBL] [Abstract][Full Text] [Related]
48. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK. Yadav AK; Kumar V; Bailey DB; Jang BC Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529 [TBL] [Abstract][Full Text] [Related]
49. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236 [TBL] [Abstract][Full Text] [Related]
51. The Specific Roles of JAK/STAT Signaling Pathway in Sepsis. Cai B; Cai JP; Luo YL; Chen C; Zhang S Inflammation; 2015 Aug; 38(4):1599-608. PubMed ID: 25676437 [TBL] [Abstract][Full Text] [Related]
52. The antagonist of the JAK-1/STAT-1 signaling pathway improves the severity of cerulein-stimulated pancreatic injury via inhibition of NF-κB activity. Chen P; Huang L; Zhang Y; Qiao M; Yao W; Yuan Y Int J Mol Med; 2011 May; 27(5):731-8. PubMed ID: 21369693 [TBL] [Abstract][Full Text] [Related]
53. Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions. Mazzarella G; MacDonald TT; Salvati VM; Mulligan P; Pasquale L; Stefanile R; Lionetti P; Auricchio S; Pallone F; Troncone R; Monteleone G Am J Pathol; 2003 Jun; 162(6):1845-55. PubMed ID: 12759242 [TBL] [Abstract][Full Text] [Related]
54. The functional role of the JAK-STAT pathway in post-infarction remodeling. El-Adawi H; Deng L; Tramontano A; Smith S; Mascareno E; Ganguly K; Castillo R; El-Sherif N Cardiovasc Res; 2003 Jan; 57(1):129-38. PubMed ID: 12504822 [TBL] [Abstract][Full Text] [Related]
55. Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease. Szelag M; Piaszyk-Borychowska A; Plens-Galaska M; Wesoly J; Bluyssen HA Oncotarget; 2016 Jul; 7(30):48788-48812. PubMed ID: 27166190 [TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Ashizawa T; Miyata H; Ishii H; Oshita C; Matsuno K; Masuda Y; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Akiyama Y Int J Oncol; 2011 May; 38(5):1245-52. PubMed ID: 21369699 [TBL] [Abstract][Full Text] [Related]
57. Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha. Zhao LJ; He SF; Liu Y; Zhao P; Bian ZQ; Qi ZT Cell Physiol Biochem; 2016; 40(1-2):77-90. PubMed ID: 27855377 [TBL] [Abstract][Full Text] [Related]
58. Negative regulators of STAT3 signaling pathway in cancers. Wu M; Song D; Li H; Yang Y; Ma X; Deng S; Ren C; Shu X Cancer Manag Res; 2019; 11():4957-4969. PubMed ID: 31213912 [TBL] [Abstract][Full Text] [Related]
59. SINBAD, structural, experimental and clinical characterization of STAT inhibitors and their potential applications. Plens-Gałąska M; Woźniak T; Wesoły J; Bluyssen HAR Sci Data; 2022 Mar; 9(1):139. PubMed ID: 35361787 [TBL] [Abstract][Full Text] [Related]
60. SUN2: A potential therapeutic target in cancer. Chen X; Chen Y; Huang HM; Li HD; Bu FT; Pan XY; Yang Y; Li WX; Li XF; Huang C; Meng XM; Li J Oncol Lett; 2019 Feb; 17(2):1401-1408. PubMed ID: 30675193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]